SARS-COV-2 VACCINE

Phase 3Vaccine

SARS-COV-2 VACCINE is one of 173 biologic programs targeting Severe Acute Respiratory Syndrome. It is currently in Phase 3.

Indications

Total Trials

Active Trials

172

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Acute Respiratory SyndromeActive, not recruiting

Kidney TransplantActive, not recruiting

Liver DiseaseActive, not recruiting

COVID-19Active, not recruiting

InfluenzaActive, not recruiting

Kidney FailureActive, not recruiting

Severe Acute Respiratory SyndromePreclinical

Active, not recruiting

Kidney TransplantPreclinical

Active, not recruiting

Liver DiseasePreclinical

Active, not recruiting

COVID-19Preclinical

Active, not recruiting

InfluenzaPhase 3

Active, not recruiting

Kidney FailurePreclinical

Active, not recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

SARS-COV-2 VACCINE

Moderna

Phase 3

2 2

Spikevax

Moderna

Preclinical

21 3

Blood Taken

HHospices Civils de Lyon

Preclinical

1 4

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 5

Hydroxychloroquine Pill

UUniversity of Calgary

Preclinical

2 6

Disease-Modifying Anti-Rheumatic Drugs

Roche

Preclinical

1 7

Saliva Collection

DDirection Centrale du Service de Santé des Armées

Preclinical

4 8

Mrna-1273.211

Moderna

Preclinical

1 9

SARS-Cov-2 Bivalent MRNA Vaccine

AAIM Vaccine Co., Ltd.

Preclinical

2 10

Coronavac COVID-19 Vaccine

HHospital Moinhos de Vento

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Active, not recruiting

Vaccine Response

NCT06605625

Clinical

Trials by Indication[1]

Severe Acute Respiratory Syndrome2 trials

Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) Immune Kidney Transplant Study (COVID-19)

Active, not recruiting·OOslo University Hospital··NCT04747522·150 enrolled

Study of a Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) Adjuvanted Inactivated Vaccine in Healthy Adults

Terminated·OOsman ERGANIS, PhD, Prof·Phase 1·NCT04866069·50 enrolled

COVID-192 trials

COVID-19 Vaccines Associated Malaise

Completed·UUniversity Hospital, Caen··NCT05234333·1,534,706 enrolled

Safety and Immune Response of COVID-19 Vaccination in Patients With Basic Disease

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University··NCT05043246·2,300 enrolled

SARS-CoV-21 trial

Humoral and Cellular Immunity Against SARS-COV-2 Vaccine in HIV-infected Patients Immunosuppressed

Completed·HHospitales Universitarios Virgen del Rocío··NCT05633927·48 enrolled

Kidney Transplant1 trial

The Response of the Immune System of Patients With End Stage Kidney Disease on Dialysis and Kidney Transplant Recipients Vaccinated for COVID-19

Unknown status·UUniversity of Ioannina··NCT04932876·100 enrolled

Kidney Failure1 trial

IMPACT OF KIDNEY FAILURE ON THE REGULATION OF HUMORAL RESPONSE TO VACCINATION

Not yet recruiting·FFondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico··NCT06635525·146 enrolled

4 more indications

Overweight1 trial

Safety and Immune Response of COVID-19 Vaccination in Overweight People With Excessive BMI

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University··NCT05043272·450 enrolled

Influenza1 trial

Study to Investigate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 Vaccine (SARS-CoV-2 [COVID-19] and Influenza) in Adults ≥50 Years of Age

Completed· Moderna logo

Moderna·Phase 3·NCT06694389·2,457 enrolled

Vaccine Response1 trial

Vaccine Responses in Cancer

Active, not recruiting·—··NCT06605625·250 enrolled

Liver Disease1 trial

Safety and Immune Response of COVID-19 Vaccination in Patients With Chronic Liver Diseases

Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University··NCT05007665·2,000 enrolled

Sources

References

[1]
ClinicalTrials.gov — 11 trial records for SARS-COV-2 VACCINE. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SARS-COV-2 VACCINE compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SARS-COV-2 VACCINE. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Moderna company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Vaccine[2]
Highest Phase: Phase 3[1]
Company: Moderna

SARS-COV-2 VACCINE

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Severe Acute Respiratory Syndrome2 trials

COVID-192 trials

SARS-CoV-21 trial

Kidney Transplant1 trial

Kidney Failure1 trial

Overweight1 trial

Influenza1 trial

Vaccine Response1 trial

Liver Disease1 trial

References

Drug Info

Quick Facts

Related News